Wegovy Priority Approval Puts Novo Nordisk Valuation And Risks In Focus [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Novo Nordisk (NYSE:NVO) received FDA approval for a higher dose of its obesity drug Wegovy under the National Priority Voucher program. The approval came through a fast track process that is currently drawing attention from regulators and lawmakers. A public FDA meeting on the voucher program is scheduled for June, adding regulatory focus to this latest decision. Novo Nordisk is a major player in diabetes and obesity care, and Wegovy is a core product in its obesity treatment portfolio. Higher-dose approval through a special voucher program places both the medicine and the company at the center of a wider policy discussion on how quickly certain drugs move through the U.S. regulatory process. For investors looking at NYSE:NVO, this development links product expansion directly to regulatory scrutiny. The way the June meeting shapes future use of the voucher program could influence timing and pathways for any additional obesity-related approvals across the sector. Stay update
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Assessing Novo Nordisk (NYSE:NVO) Valuation After Recent Weak Share Performance [Yahoo! Finance]Yahoo! Finance
- Obesity drugmaker Kailera plans an IPO [Yahoo! Finance]Yahoo! Finance
- Mars CEO gets board role at GLP-1 supplier Novo Nordisk [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk (NVO) Shares Up Since Jim Cramer Said He Was A Buyer [Yahoo! Finance]Yahoo! Finance
- Stocks, sectors, and charts this strategist is watching [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/30/26 - Form 6-K
- 3/27/26 - Form 6-K
- 3/27/26 - Form 6-K
- NVO's page on the SEC website